GHK-Cu vs Matrixyl 3000
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Copper Peptide, Glycyl-L-histidyl-L-lysine copper
GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Also: Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7
Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- GHK-Cu has stronger research evidence (Human Trials) compared to Matrixyl 3000 (Limited Research).
Detailed Comparison
| Attribute | GHK-Cu | Matrixyl 3000 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHK has a strong affinity for copper(II) ions and forms the GHK-Cu complex, which is thought to deliver copper to cells for copper-dependent processes such as connective-tissue formation and antioxidant defense. Its most striking documented activity is broad gene-expression modulation: in cultured human cells, GHK shifts the expression of a large fraction of genes, tending to upregulate tissue-repair genes and downregulate some inflammatory pathways. It stimulates fibroblasts to produce collagen and other extracellular-matrix proteins, supports keratinocyte and blood-vessel activity, and shows antioxidant and anti-inflammatory effects in lab models. Importantly, the copper-binding hypothesis does not fully explain these gene effects, and researchers note the precise mechanism is not yet fully understood. | Both peptides are matrikines, short collagen-derived signals the skin treats as repair instructions. Palmitoyl tripeptide-1 nudges fibroblasts to produce more collagen, elastin and fibronectin, the scaffolding that keeps skin firm. Palmitoyl tetrapeptide-7 works on the other side of the equation by tamping down release of interleukin-6, an inflammatory messenger that climbs with age and quietly accelerates matrix breakdown, which in turn is thought to limit collagen glycation damage. As with the original Matrixyl, the palmitoyl tails are there to ferry these water-loving peptides through the skin barrier. The combined claim is build more, lose less. |
| Common Dosing | 1-2 mg daily (injection) or 0.05% topical Once daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection or topical application | Topical (serums, creams) |
| Typical Duration | Varies by application | Ongoing use for maintained effects |
| Best Time to Take | Evening (for skin/recovery) | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Much of the mechanistic and efficacy evidence is from cell culture and animal studies. In animals, GHK and GHK-containing dressings improved wound contraction, granulation tissue and collagen deposition in rabbit and rat wounds, and showed protective effects in lung-injury models. In cells, GHK increases collagen, elastin and growth-factor production by fibroblasts and protects keratinocytes from UV damage. Human evidence exists but is limited to small cosmetic trials: facial-cream and eye-cream studies in modest numbers of women (for example a 71-subject facial study and a 41-subject eye-cream study) reported improvements in skin density, thickness and wrinkle appearance. These trials are small and focused on topical skin endpoints, so they do not establish injected or systemic benefits, and there are no large independent randomized trials. Honest summary: strong lab and animal data plus encouraging small topical human studies, but evidence for injected use is preliminary. | Matrixyl 3000 has a coherent, biologically reasonable mechanism, and in vitro studies do show its components stimulating fibroblast proliferation and synthesis of collagen types I, III, IV and VII, with the tetrapeptide reducing IL-6. The catch for a careful reader is that most of the supporting clinical work, including the commonly cited 12-week trials reporting reductions in wrinkles and skin laxity, originates from or was sponsored by the manufacturer rather than independent labs, and large published placebo-controlled trials specific to this exact complex are sparse. The strongest truly independent peptide evidence in this family is still the original Pal-KTTKS Matrixyl data. So Matrixyl 3000 is best described as a sensible, well-tolerated upgrade on paper with solid mechanistic and in vitro backing, but with human efficacy that rests heavily on industry sources rather than rigorous third-party trials. It targets collagen and inflammation, not muscle, so expectations should be texture and firmness, not Botox-like smoothing. |
Frequently Asked Questions: GHK-Cu vs Matrixyl 3000
What is the difference between GHK-Cu and Matrixyl 3000?
GHK-Cu is a skin & hair peptide that ghk-cu is the copper(ii) complex of ghk, a naturally occurring human tripeptide (glycyl-l-histidyl-l-lysine) found in blood plasma, saliva and urine, whose levels decline with age. it is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. it is not an fda-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies. Matrixyl 3000 is a skin & hair peptide that matrixyl 3000 is sederma's follow-up to the original matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (pal-ghk) and palmitoyl tetrapeptide-7 (pal-gqpr). the idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. it is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHK-Cu or Matrixyl 3000?
Neither is universally "better" - the choice depends on your specific goals. GHK-Cu is typically used for skin & hair purposes, while Matrixyl 3000 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHK-Cu and Matrixyl 3000 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHK-Cu and Matrixyl 3000 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.